Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Hormaomycin (HB3932)
Description:Selective peptide lactone antibacterial agent. Antibiotic.
Purity:>98%
Kirromycin (HB3951)
Description:Antibacterial antibiotic and protein synthesis inhibitor
Purity:>96%
Linezolid (HB4443)
Description:Inhibits protein synthesis in gram-positive bacteria. Antibiotic.
Purity:>98%
Malformin C (HB3966)
Description:Antibiotic. Potent G2 checkpoint cell cycle arrest inhibitor
Purity:>95%